Drug Landscape ›
Ketorolac 15mg ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 16
Most-reported reactions
Headache — 3 reports (18.75%) Nausea — 3 reports (18.75%) Infusion Related Reaction — 2 reports (12.5%) Vomiting — 2 reports (12.5%) Abdominal Discomfort — 1 report (6.25%) Abdominal Pain — 1 report (6.25%) Acute Kidney Injury — 1 report (6.25%) Anaemia — 1 report (6.25%) Ascites — 1 report (6.25%) Bladder Dilatation — 1 report (6.25%)
Source database →
Ketorolac 15mg in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Ketorolac 15mg approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Ketorolac 15mg in United States?
Cairo University is the originator. The local marketing authorisation holder may differ — check the official source linked above.